Innoviva, Inc. (INVA)
21.33
-0.02
(-0.09%)
USD |
NASDAQ |
Sep 04, 16:00
21.31
-0.02
(-0.09%)
After-Hours: 20:00
Innoviva Research and Development Expense (Quarterly) : 5.19M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 5.19M |
| March 31, 2026 | 5.241M |
| December 31, 2025 | 4.555M |
| September 30, 2025 | 13.67M |
| June 30, 2025 | 7.983M |
| March 31, 2025 | 4.396M |
| December 31, 2024 | 3.665M |
| September 30, 2024 | 3.551M |
| June 30, 2024 | 2.56M |
| March 31, 2024 | 3.878M |
| December 31, 2023 | 2.356M |
| September 30, 2023 | 3.989M |
| June 30, 2023 | 14.99M |
| March 31, 2023 | 12.59M |
| December 31, 2022 | 9.985M |
| September 30, 2022 | 11.72M |
| June 30, 2022 | 13.88M |
| March 31, 2022 | 5.838M |
| December 31, 2021 | 0.04M |
| September 30, 2021 | 0.449M |
| June 30, 2021 | 0.038M |
| March 31, 2021 | 0.049M |
| December 31, 2020 | 0.219M |
| September 30, 2020 | 1.01M |
| June 30, 2020 | 0.559M |
| Date | Value |
|---|---|
| March 31, 2020 | |
| December 31, 2019 | |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.342M |
| September 30, 2017 | 0.311M |
| June 30, 2017 | 0.348M |
| March 31, 2017 | 0.354M |
| December 31, 2016 | 0.345M |
| September 30, 2016 | 0.286M |
| June 30, 2016 | 0.37M |
| March 31, 2016 | 0.392M |
| December 31, 2015 | 0.722M |
| September 30, 2015 | 0.547M |
| June 30, 2015 | 0.638M |
| March 31, 2015 | 0.712M |
| December 31, 2014 | 0.777M |
| September 30, 2014 | 1.909M |
| June 30, 2014 | 2.125M |
| March 31, 2014 | 43.39M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Zevra Therapeutics, Inc. | 4.486M |
| Collegium Pharmaceutical, Inc. | -- |
| CorMedix, Inc. | 6.684M |
| ANI Pharmaceuticals, Inc. | 14.75M |
| Corcept Therapeutics, Inc. | 53.89M |